Janus Henderson Group
THRX

Janus Henderson Group’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Janus Henderson Group’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-633,423
Closed -$5.93M – 2602
2023
Q2 		$5.93M Buy
633,423
+172,695
+37% +$1.7M ﹤0.01% 812
2023
Q1 		$4.07M Buy
+460,728
New +$4.52M ﹤0.01% 937

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group's THRX Position: Q3 2023 in Review

Janus Henderson Group sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q3 2023, closing a stake of 633,423 shares — an estimated $5.93M sold.

Janus Henderson Group first reported a position in THRX in Q1 2023 and held it in 2 quarters. The position peaked at $5.93M in Q2 2023. 63 funds tracked by Wall St. Rank hold THRX as of Q3 2023.

  • Janus Henderson Group reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Janus Henderson Group sold 633,423 Theseus Pharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $5.93M.
  • Janus Henderson Group first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Janus Henderson Group's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $5.93M in Q2 2023.
  • 63 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on Janus Henderson Group's 13F filing for Q3 2023, filed 14 Nov 2023.